No products in the cart.
Doxorubicin Liposome Injection
$2.00
is a liposomal formulation of doxorubicin, offering enhanced circulation time and reduced cardiotoxicity compared to the traditional form. Supplied as 20mg per 10mL vial, it is strictly for laboratory research use only—not for clinical or human application. Please consult the staff for other purposes.
Description
Doxorubicin Liposome Injection Specifications
| Attribute | Details |
|---|---|
| Product Name | Doxorubicin Hydrochloride Liposome Injection |
| Concentration | 20?mg doxorubicin per 10mL vial |
| Dosage Form | Intravenous liposomal injection (vial) |
| Approval No. | China NMPA H20234166 |
| Product Code | 86904641003522 |
| Manufacturer | Zhejiang Haizheng Pharmaceutical Co., Ltd. |
| Barcode | 6976309470001 |
| Intended Use | Laboratory research use only — Not for human or veterinary use |
Doxorubicin Liposome Injection Mechanism of Action
Liposome-encapsulated doxorubicin intercalates DNA and inhibits topoisomerase II, preventing DNA replication and triggering apoptosis. The liposomal formulation enhances delivery to tumors while lowering cardiotoxicity risk. annaliitalianidichirurgia.iten.wikipedia.org
Research & Clinical Background
Use Case: Preferentially studied in liposome-delivery cancer models (e.g., lymphoma), especially in elderly-DLBCL preclinical research.
Advantages over free doxorubicin include prolonged circulation time and improved tumor targeting.
Pharmacology: Highly protein bound (~75%), elimination half-life: multiple phases; liver metabolism. Suitable for chemotherapy and pharmacokinetic study models.
Research Applications
DNA-intercalation and cytotoxicity assays
Liposomal drug-delivery and pharmacokinetics
Preclinical cancer models, especially lymphoma and solid tumor xenografts
Comparative cardiotoxicity studies vs free doxorubicin
Research Use Disclaimer
This product is provided strictly for laboratory research and development use only.
Additional information
| Weight | 1.1 kg |
|---|---|
| Dimensions | 26 × 24 × 25 cm |
1 review for Doxorubicin Liposome Injection
Related products
Cetuximab NO1 Injection
Cetuximab NO1 Injection, 100mg in 50mL vial, is a biosimilar developed by Sichuan Kelun Botai Biopharma, branded as Datalai®. Approved in China (NMPA S20250006), this EGFR-targeting monoclonal antibody is ideal for laboratory or analytical research in oncology $1.00Fulzerasib Tablets (Dupert) – 150mg
Fulzerasib (Dupert) is an orally active KRAS G12C inhibitor, conditionally approved in China for advanced non–small-cell lung cancer (NSCLC) with KRAS G12C mutation. Manufactured by CindaBio, NMPA approved under H20240035 (drug code: 86985200000015). Strictly for laboratory research use only—NOT for clinical or human consumption. $1.00Temozolomide Capsules
Temozolomide 100mg capsules, 5 count box, produced by Shanghai ChuanNuo Pharmaceuticals Co., Ltd., approved under NMPA H20234716. A key alkylating agent for glioblastoma and astrocytoma research—ideal for preclinical oncology models. $1.00Pirtobrutinib Tablets
Pirtobrutinib Tablets (brand name: Jaypirca) is the world’s first non-covalent BTK inhibitor, provided here as 100?mg oral film?coated tablets. Manufactured by Lilly del Caribe, Inc. and approved for import in China (NMPA No. HJ20240116; code 86978403001613). Supplied with clear indication for research/investigational use only, not for human therapeutic use. $2.00
bradschi –
Good product, great service, thank you